Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ImmunityBio ( (IBRX) ) has issued an announcement.
On December 12, 2025, ImmunityBio announced that the European Medicines Agency recommended conditional marketing authorization for ANKTIVA® in combination with BCG for treating non-muscle invasive bladder cancer (NMIBC) carcinoma in situ in Europe. This recommendation marks the first immunotherapy for NMIBC with carcinoma in situ to receive such a positive recommendation in Europe, addressing a significant unmet need for patients unresponsive to BCG, whose primary option has been bladder removal surgery. The decision is based on a single-arm trial showing promising response rates, and it highlights ImmunityBio’s efforts to expand access to innovative treatments in Europe, potentially impacting the company’s market positioning and offering new hope for patients.
The most recent analyst rating on (IBRX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.
Spark’s Take on IBRX Stock
According to Spark, TipRanks’ AI Analyst, IBRX is a Neutral.
ImmunityBio’s overall stock score is primarily impacted by its poor financial performance and valuation metrics. The company’s financial instability, negative equity, and ongoing losses are significant concerns. Technical analysis indicates a bearish trend, further weighing down the score. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on IBRX stock, click here.
More about ImmunityBio
ImmunityBio is a vertically-integrated biotechnology company focused on developing next-generation therapies to enhance the natural immune system for combating cancers and infectious diseases. The company offers a range of immunotherapy and cell therapy platforms aimed at creating durable and safe protection against diseases, including cancer vaccines and immunotherapies that potentially reduce the need for high-dose chemotherapy.
Average Trading Volume: 10,111,851
Technical Sentiment Signal: Sell
Current Market Cap: $2.27B
Learn more about IBRX stock on TipRanks’ Stock Analysis page.